Related by context. Frequent words. (Click for all words.) 63 Vitaros 63 Clinical Trial Application 59 Pivotal Phase III 58 Biologics License Application BLA 57 FDA Accepts 57 Biologics License Application 57 Drug Application 56 FDA approvable letter 56 application sNDA 55 sNDA 55 Investigational 55 Complete Response 55 Ceftobiprole 55 Augment Bone Graft 54 Act PDUFA date 54 Marketing Authorization Application 54 FDA Clearance 54 Extended Release Tablets 53 Swissmedic 53 Onsolis 53 USFDA approval 53 Marketing Authorization 53 Marketing Authorization Application MAA 53 Extended Release 53 BioDelivery Sciences 53 Presents Positive 53 Phase III Clinical Trial 52 Investigational Device Exemption 52 supplemental Biologics License Application 52 Pennsaid R 52 Pirfenidone 52 Abstral 52 Citizen Petition 52 submitted Biologics License 52 Generic Version 52 Medicis Pharmaceutical Corporation 51 European Medicines Evaluation 51 FDA Clears 51 ELND# 51 Rebif ® 51 sBLA 51 Drug Administration USFDA 51 Panzem R 51 Factive 51 Market Approval PMA 51 Investigational Device Exemption IDE 51 Orphan Drug Status 51 Paragraph IV 51 cervical cancer vaccine Cervarix 51 NEBIDO 50 REVLIMID lenalidomide 50 Pivotal Trial 50 dalbavancin 50 Apricus Bio 50 Mutual Recognition Procedure 50 INDs 50 Oral Solution 50 MHLW 50 orphan designation 50 Drug Administration FDA 50 Avastin bevacizumab 50 NOXAFIL 50 Complete Response letter 50 Ceragenix 50 New Drug Application 50 liprotamase 50 Upsher Smith 50 BEMA Fentanyl 49 Priority Review 49 Clevudine 49 Rotarix R 49 Telavancin 49 ZALBIN 49 Commercialization Agreement 49 IND submission 49 Loramyc ® 49 Anika Therapeutics 49 IMVAMUNE R 49 alvimopan 49 Octreotide 49 Urocidin 49 USFDA 49 Welfare MHLW 49 Drug Candidate 49 Nasdaq VRTX 49 FDA Approval 49 Zolinza 49 QNEXA 49 Completes Enrollment 49 Orphan Drug status 49 ONSOLIS 49 Oracea 49 pediatric exclusivity 49 Clinical Trial Results 49 Influenza Vaccine 49 Plenaxis R 49 GEM #S 49 Natalizumab 49 Full Prescribing Information 48 Tranzyme Pharma 48 methylnaltrexone